KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 112 filers reported holding KEROS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $400,795 | -88.0% | 12,572 | -84.8% | 0.00% | -100.0% |
| Q2 2023 | $3,330,560 | -10.8% | 82,891 | -5.2% | 0.00% | 0.0% |
| Q1 2023 | $3,731,809 | +578.7% | 87,396 | +663.3% | 0.00% | – |
| Q4 2022 | $549,829 | +81.5% | 11,450 | +42.3% | 0.00% | – |
| Q3 2022 | $303,000 | +6.3% | 8,044 | -21.7% | 0.00% | – |
| Q2 2022 | $285,000 | -48.4% | 10,275 | +1.3% | 0.00% | – |
| Q1 2022 | $552,000 | -15.3% | 10,140 | -9.0% | 0.00% | – |
| Q4 2021 | $652,000 | +52.7% | 11,146 | +3.4% | 0.00% | – |
| Q3 2021 | $427,000 | -9.0% | 10,777 | -2.6% | 0.00% | – |
| Q2 2021 | $469,000 | -20.9% | 11,064 | +14.6% | 0.00% | – |
| Q1 2021 | $593,000 | -19.4% | 9,652 | -7.6% | 0.00% | – |
| Q4 2020 | $736,000 | +394.0% | 10,444 | +171.1% | 0.00% | – |
| Q3 2020 | $149,000 | +12.9% | 3,852 | +9.6% | 0.00% | – |
| Q2 2020 | $132,000 | – | 3,516 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 276,000 | $7,626,000 | 3.44% |
| First Light Asset Management, LLC | 598,333 | $16,532,000 | 1.92% |
| Fairmount Funds Management LLC | 272,498 | $7,529,000 | 1.72% |
| Deep Track Capital, LP | 739,528 | $20,433,000 | 1.34% |
| Nantahala Capital Management | 911,901 | $25,196,000 | 1.26% |
| Octagon Capital Advisors LP | 152,249 | $4,207,000 | 1.12% |
| CHI Advisors LLC | 103,429 | $2,858,000 | 1.09% |
| Altium Capital Management LP | 88,000 | $2,431,000 | 0.97% |
| Orbimed Advisors | 1,679,417 | $46,402,000 | 0.84% |
| Parkman Healthcare Partners LLC | 47,788 | $1,320,000 | 0.49% |